Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality

This publication has 34 references indexed in Scilit:

• Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
  Clinical Cancer Research, 2012
• Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer
  British Journal of Cancer, 2012
• Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients
  Annals of Oncology, 2011
• Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner
  Cell Metabolism, 2010
• Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer
  Clinical Cancer Research, 2010
• Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
  Cancer Research, 2009
• Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study
  Cancer Causes & Control, 2009
• Association of Diabetes With Prostate Cancer Risk in the Multiethnic Cohort
  American Journal of Epidemiology, 2009
• Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus
  JAMA, 2008
• Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
  The Lancet Oncology, 2008